Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
Upasana Ray(Mayo Clinic), Viji Shridhar(Mayo Clinic in Arizona), Eleftheria Kalogera(Mayo Clinic), Yinan Xiao(Mayo Clinic), Grace Cullen(Mayo Clinic in Arizona), Julie Staub(Mayo Clinic), Ann L. Oberg(University of Minnesota), Krista M. Goergen(Mayo Clinic in Florida), Debarshi Roy, Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), Ling Jin(Mayo Clinic in Arizona), Prabhu Thirusangu(Mayo Clinic in Arizona)
Cited by 25
Related Papers
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer
|Science|2009|356
Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer
|Journal of Biological Chemistry|2003|248
HSulf-1 Inhibits Angiogenesis and Tumorigenesis <i>In vivo</i>
|Cancer Research|2006|135
Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer
|Journal of Biological Chemistry|2007|80